CoMotion Labs @ Fluke Hall, 4000 Mason Road
Suite 300, Box 352141
About M3 BiotechnologyM3 Biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. The lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. The company’s research has been funded by the Alzheimer’s Drug Discovery Foundation, Washington’s Life Sciences Discovery Fund, W Fund, WRF Capital, Dolby Family Ventures and other private investors.
CEO: Leen Kawas
CFO: Glenna Mileson
CSO: Joseph Harding
Please click here for M3 Biotechnology job opportunities.
FOLLOW M3 BIOTECHNOLOGY:
Tweets by M3 Biotechnology
6 articles with M3 Biotechnology
Alzheimer's Association Awards M3 Biotechnology, Inc. with Part the Cloud to RESCUE Grant to Support Phase 2 Clinical Trials of NDX-1017 to treat Alzheimer's
M3 Biotechnology, Inc., today announced receipt of a Part the Cloud to RESCUE grant from the Alzheimer's Association.
M3 Biotechnology begins testing of its novel therapy NDX-1017 in individuals with Alzheimer’s disease or mild cognitive impairment
Recruitment underway in the United States and France.
M3 Biotechnology announced that Deborah (Debby) C. Hopkins has been elected to the Company’s Business and Strategy Advisory Board effective July 10, 2018.
M3 Biotechnology is a clinical stage company with a novel platform of disease-modifying regenerative therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer's. M3's lead asset, NDX-1017, modifies growth factor systems and is advanced as a first-in-class, disease-modifying treatment with the potential to restore lost connections between brain cells, turning degeneration into regeneration.
M3 Biotechnology Launches Clinical Trials For Alzheimer’s Disease Drug Focused On Restoring Lost Connections In The Brain
A six-year-old biotech company at the leading edge of regenerative medicine is bringing a therapy for Alzheimer’s to Phase I clinical trials that is expected to slow or stop disease progression as indicated by pre-clinical studies, announced M3 CEO Leen Kawas.